
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
May 23, 2018

SYNDAX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(state or other jurisdiction of incorporation)

001-37708
(Commission File Number)

32-0162505
(I.R.S. Employer Identification No.)

Building D, Floor 3
35 Gatehouse Drive
Waltham, Massachusetts
(Address of principal executive offices)

02451
(Zip Code)

Registrant's telephone number, including area code: **(781) 419-1400**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07. Submission of Matters to a Vote of Security Holders.

Syndax Pharmaceuticals, Inc. (the “*Company*”) held its annual meeting of stockholders (the “*Annual Meeting*”) on May 23, 2018. The results for each of the proposals submitted to a vote of the *Company*’s stockholders at the Annual Meeting are set forth below. The proposals set forth below are described in detail in the *Company*’s definitive proxy statement filed with the Securities and Exchange Commission on April 10, 2018. The voting results were as follows:

Proposal 1: The *Company*’s stockholders elected both nominees for director to serve a three-year term until the 2021 Annual Meeting, or until their respective successors are duly elected and qualified, by the votes set forth in the table below:

<u>Nominee</u>	<u>For</u>	<u>Against</u>	<u>Broker Non-Votes</u>
Henry Chen	10,313,293	1,800,907	5,278,332
Luke Evin, Ph.D.	10,077,732	2,036,778	5,278,332

Proposal 2: The *Company*’s stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the *Company* for the fiscal year ending December 31, 2018 by the votes set forth in the table below:

<u>For</u>	<u>Against</u>	<u>Abstain</u>
17,360,374	21,049	13,946

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SYNDAX PHARMACEUTICALS, INC.

By: /s/ Briggs W. Morrison, M.D.

Briggs W. Morrison, M.D.

Chief Executive Officer

Dated: May 25, 2018